Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115049 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von C Ertl und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany; SERIO-Registry (www.serio-registry.org). Hauptthemen laut MEDLINE: Photopheresis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: Checkpoint inhibitor-induced steroid-refractory (sr) and steroid-dependent (sd) immune-related adverse events (irAE) account for about 11 % of irAE. Although these patients face worse outcomes due to irAE mortality and/or sustained immunosuppression, which impairs anti-tumor response, there is no established second-line treatment based on prospective trial data. METHODS: This prospective comparative study investigates outcomes of extracorporeal photopheresis (ECP), an immunomodulating therapy, versus second-line immunosuppressants (SLI) in sr/sd-irAE. The primary endpoint was longitudinal change in immunophenotype; secondary endpoints were outcome of irAE and tumor response. Patient demographics, quality of life (EORTC QLQ-C30; global health status (GHS/QoL)) and longitudinal blood samples were analyzed at baseline; in weeks 1, 4, 8, and 12. RESULTS: At interim analysis, 21 patients (11 ECP, 10 SLI) with 7 different sr/sd-irAE were included. Compared with the SLI group, the ECP group demonstrated a higher clinical response rate of irAE (93 % vs. 80 %; 95 % CI 0.83-1.92; P = 0.54) and a better GHS/QoL score throughout all follow-up visits. ECP patients showed a numerically higher overall survival (23 vs. 12 months; 95 % CI 0.02-3.02; P = 0.27) and lower cancer progression rates (33 % vs. 67 %; 95 % CI 0.09-1.60; P = 0.52). Immunophenotyping revealed changes in immune cell populations and the regulation of immune checkpoints. There were no significant safety issues in either treatment group. CONCLUSION: This prospective comparative study supports the clinical efficacy of ECP in the treatment of sr/sd-irAE in comparison to the SLI cohort. Thus, ECP represents a potential treatment option for this indication, given its good safety profile while maintaining anti-tumor response. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05700565, https://classic. CLINICALTRIALS: gov/ct2/show/NCT05700565.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany; SERIO-Registry (www.serio-registry.org).
- Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany.
- Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany; Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany; Institute of Anthropology Francisc I. Rainer, Romanian Academy, Bucharest, Romania.
Zitieren
APA
Ertl, C., Ruf, T., Hammann, L., Piseddu, I., Wang, Y., Schmitt, C., Garza Vazquez, X., Kabakci, C., Bonczkowitz, P., de Toni, E. N., David-Rus, R., Srour, J., Tomsitz, D., French, L. E., & Heinzerling, L. (2024). Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115049
Vancouver
Ertl C, Ruf T, Hammann L, Piseddu I, Wang Y, Schmitt C, et al. Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115049
BibTeX
@article{Ertl2024,
author = {Ertl, C and Ruf, T and Hammann, L and Piseddu, I and Wang, Y and Schmitt, C and Garza Vazquez, X and Kabakci, C and Bonczkowitz, P and de Toni, E N and David-Rus, R and Srour, J and Tomsitz, D and French, L E and Heinzerling, L},
title = {Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115049}
}
EUVIMED